Table 2 Clinical outcomes according to different BRCA1 status and different levels of stromal tumor-infiltrating lymphocytes

Tumor BRCA1-PM, sTILs < 50% (n = 77)

 0 to 10 years

28

63.0 (53.0–74.9)

28

62.5 (52.4–74.5)

3

4.0 (0.0–8.3)

 10 to 15 years

2

60.3 (50.2–72.4)

2

59.5 (49.3–71.9)

1

5.4 (0.1–10.3)

Tumor BRCA1-PM, sTILs ≥ 50% (n = 66)

 0 to 10 years

2

97.0 (92.9–100.0)

1

98.5 (95.6–100.0)

3

4.5 (0.0–9.4)

 10 to 15 years

0

97.0 (92.9–100.0)

0

98.5 (95.6–100.0)

2

7.6 (1.0–13.8)

gBRCA1m, sTILs < 50% (n = 61)

 0 to 10 years

28

54.1 (42.9–68.2)

25

52.4 (40.3–68.0)

16

26.2 (15.0–36.0)

 10 to 15 years

2

50.8 (39.7–65.0)

0

52.4 (40.3–68.0)

3

31.2 (19.5–41.2)

gBRCA1m, sTILs ≥ 50% (n = 44)

 0 to 10 years

7

84.1 (73.9–95.6)

3

91.4 (82.5–100.0)

27

61.4 (44.8–73.0)

 10 to 15 years

3

77.1 (65.6–90.7)

0

91.4 (82.5–100.0)

2

65.9 (49.6–77.0)

sBRCA1m, sTILs < 50% (n = 13)

 0 to 10 years

6

53.8 (32.6–89.1)

7

46.2 (25.7–83.0)

0

0.0 (0.0–0.0)

 10 to 15 years

0

53.8 (32.6–89.1)

0

46.2 (25.7–83.0)

0

0.0 (0.0–0.0)

sBRCA1m, sTILs ≥ 50% (n = 8)

 0 to 10 years

1

87.5 (67.3–100.0)

1

87.5 (67.3–100.0)

1

12.5 (0.0–32.7)

 10 to 15 years

0

87.5 (67.3–100.0)

0

87.5 (67.3–100.0)

0

12.5 (0.0–32.7)

BRCA1-non-altered, sTILs < 50% (n = 77)

 0 to 10 years

25

66.2 (56.3–77.9)

25

66.0 (56.1–77.8)

5

6.8 (0.9–12.3)

 10 to 15 years

4

60.8 (50.6–73.0)

3

61.4 (51.1–73.8)

4

12.3 (4.6–19.4)

BRCA1-non-altered, sTILs ≥ 50% (n = 66)

 0 to 10 years

7

85.7 (76.4–96.1)

4

91.0 (82.9–99.8)

6

12.2 (2.6–20.9)

 10 to 15 years

1

83.6 (73.8–94.7)

0

91.0 (82.9–99.8)

2

16.3 (5.4–26.0)